{
    "clinical_study": {
        "@rank": "156337", 
        "acronym": "FG-treatment", 
        "arm_group": [
            {
                "arm_group_label": "PRFG treatment", 
                "arm_group_type": "Experimental", 
                "description": "As described in our previous study, platelet-rich cryoprecipitate and thrombin were obtained from 300-400ml whole blood of each patient enrolled in the PRFG group and then frozen at -20\u00b0C for storage. Prior to application, frozen cryoprecipitate and thrombin stored were thawed in a 37\u00b0C water bath. Aminomethylbenzoic Acid (1ml: 1mg, Sigma-Aldrich, St Louis, MO) was added into the cryoprecipitate in the volume ratio of 1:10."
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Sham Comparator", 
                "description": "Patients in this group only received standard of care when their fistula output < 200ml/24h."
            }, 
            {
                "arm_group_label": "Commercial FG", 
                "arm_group_type": "Experimental", 
                "description": "Commercial FG (Zhejiang Puji Porcine fibrin sealant) was applied to close fistulas."
            }
        ], 
        "brief_summary": {
            "textblock": "Adjuvant use of fibrin glue (FG) in the fistula tract has been shown to promote closure of\n      low-output enterocutaneous fistulas (ECFs). The primary objectives of this study are to\n      compare the clinical efficacy, safety of autologous platelet-rich fibrin glue (PRFG),\n      commercial fibrin glue, and control therapy in the management of patients with low-output\n      volume ECFs."
        }, 
        "brief_title": "Glue Application in the Treatment of Low-Output Fistulas", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Low-output External Gastrointestinal Fistula", 
        "condition_browse": {
            "mesh_term": [
                "Fistula", 
                "Intestinal Fistula"
            ]
        }, 
        "detailed_description": {
            "textblock": "-  This is a prospective, randomized, multi-centered study clinical, safety and economic\n           outcome of ECFs patients.\n\n        -  Subjects are randomized to one of 3 groups:\n\n             -  Group 1: Autologous PRFG-treatment [PRFG + Standard of care (SOC)]\n\n             -  Group 2: Commercial FG-treatment [FG + Standard of care (SOC)]\n\n             -  Group 3: Control (SOC only)\n\n        -  Study will include three phases:\n\n             -  Phase 1: Screening, consent and enrollment\n\n             -  Phase 2: Patients will receive either PRFG, commercial FG, or SOC only for 14 days\n\n             -  Phase 3: Follow up: for patients with closed fistula within 14 days, we will\n                follow up them for 6 months. For patients whose fistulas were still open will be\n                treated with other therapeutic option and follow up for 6 months after closure."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with a single tubular ECF\n\n          -  Low output volume (<200 ml/24h)\n\n          -  Tract length >2cm\n\n          -  Tract diameter < 1cm\n\n        Exclusion Criteria:\n\n          -  Cancer-infiltrated fistula\n\n          -  Abscess\n\n          -  Foreign bodies\n\n          -  Distal bowel obstruction\n\n          -  Inflammatory Bowel Disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01828892", 
            "org_study_id": "20120819"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "PRFG treatment", 
                    "Commercial FG"
                ], 
                "description": "A forward-viewing fistula-fiberscope (EndoView, Outai Medical Equipment, Shanghai, China), with 15cm length and 5mm width of fiber optical wire, was inserted into the fistula tract to accomplish endoscopic visualization. Briefly, the fistula-fiberscope assisted procedure was carried out percutaneously, allowing the exposure of internal hole and the whole tracts, followed by insertion of this catheter with distal mixing device.", 
                "intervention_name": "Endoscopy exploration and glue application", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Control", 
                "description": "A forward-viewing fistula-fiberscope (EndoView, Outai Medical Equipment, Shanghai, China), with 15cm length and 5mm width of fiber optical wire, was inserted into the fistula tract to accomplish endoscopic visualization.", 
                "intervention_name": "Endoscopy exploration", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": [
                    "PRFG treatment", 
                    "Control", 
                    "Commercial FG"
                ], 
                "description": "Antibacterial therapy in patients with signs of systemic sepsis or local inflammation with pain", 
                "intervention_name": "Antibiotics (ceftazidime, cefotaxime, or meropenem, with or without vancomycin)", 
                "intervention_type": "Drug", 
                "other_name": "ceftazidime, cefotaxime, or meropenem, with or without vancomycin"
            }, 
            {
                "arm_group_label": [
                    "PRFG treatment", 
                    "Control", 
                    "Commercial FG"
                ], 
                "description": "Nutritional replacement and bowel rest via enteral or parenteral nutrition", 
                "intervention_name": "Nutrition support", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Anti-Bacterial Agents", 
                "Cefotaxime", 
                "Cefoxitin", 
                "Ceftazidime", 
                "Vancomycin", 
                "Meropenem", 
                "Antibiotics, Antitubercular", 
                "Fibrin Tissue Adhesive"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Autologous platelet rich fibrin glue", 
            "Enterocutaneous fistulas", 
            "Single low output GI fistulas"
        ], 
        "lastchanged_date": "March 18, 2014", 
        "location": {
            "contact": {
                "email": "Jiananr@gmail.com", 
                "last_name": "Jianan Ren, MD", 
                "phone": "862580860108"
            }, 
            "facility": {
                "address": {
                    "city": "Nanjing", 
                    "country": "China", 
                    "state": "Jiangsu", 
                    "zip": "210002"
                }, 
                "name": "Jinling Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized Controlled Trial to Evaluate Fibrin Glue Application in the Treatment of Low-Output Enterocutaneous Fistulas", 
        "other_outcome": {
            "description": "Hospital cost upon enrollment, Hospital cost during entire hospital stay, Cost between fistula onset and final outcome", 
            "measure": "Economic outcome", 
            "safety_issue": "No", 
            "time_frame": "From fistula onset to the end of treatment, which is at least 180 days"
        }, 
        "overall_contact": {
            "email": "jiananr@gmail.com", 
            "last_name": "Jianan Ren, MD", 
            "phone": "862580860108"
        }, 
        "overall_contact_backup": {
            "email": "xiuwenwoo@gmail.com", 
            "last_name": "XIUWEN WU", 
            "phone": "862580860008"
        }, 
        "overall_official": {
            "affiliation": "Jinling Hospital, China", 
            "last_name": "Jianan Ren, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "China: Food and Drug Administration", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The fraction of patients with complete closure of fistula during 14 days", 
            "measure": "Closure rates up to 14 days", 
            "safety_issue": "No", 
            "time_frame": "14 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01828892"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Jinling Hospital, China", 
            "investigator_full_name": "Jianan Ren", 
            "investigator_title": "Vice president of department of surgery, Jinling Hospital", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Incidence of adverse events and severe adverse events up to 180 days (defined as an event that was fatal or life-threatening, led to additional hospitalization or disability, or required an intervention to prevent one of these outcomes)", 
            "measure": "Number of adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "Participants will be followed for at least 180 days"
        }, 
        "source": "Jinling Hospital, China", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jinling Hospital, China", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}